同步放化疗-话题@MedSci

#同步放化疗#

35篇内容 | 867人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1516690, encodeId=7376151669008, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=Thorac Cancer：基于PET检查分期的食管鳞癌根治术后辅助同步放化疗(ACCRT)的疗效, objectType=article, longId=728905, objectId=5bbce28905b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bbce28905b8, replyNumber=0, likeNumber=0, createdTime=2022-06-10, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bbce28905b8, moduleTitle=Thorac Cancer：基于PET检查分期的食管鳞癌根治术后辅助同步放化疗(ACCRT)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bbce28905b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516689, encodeId=995a1516689e2, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适, objectType=article, longId=300448, objectId=e70c30044809, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e70c30044809, replyNumber=0, likeNumber=32, createdTime=2022-03-12, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e70c30044809, moduleTitle=Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e70c30044809)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516688, encodeId=ab261516688fc, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=Front Oncol：宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素, objectType=article, longId=295136, objectId=26002951366f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26002951366f, replyNumber=0, likeNumber=27, createdTime=2022-02-06, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26002951366f, moduleTitle=Front Oncol：宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26002951366f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516686, encodeId=532715166869a, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, objectType=article, longId=293024, objectId=52cc2930249f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52cc2930249f, replyNumber=0, likeNumber=39, createdTime=2021-12-30, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52cc2930249f, moduleTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52cc2930249f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516687, encodeId=8bf5151668ebe, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=Ann Oncol：局限期小细胞肺癌(LD-SCLC)患者同步放化疗+PCI后使用nivolumab+ipilimumab免疫联合强化治疗并不能改善患者的预后, objectType=article, longId=292797, objectId=618f292e9792, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618f292e9792, replyNumber=0, likeNumber=44, createdTime=2021-12-28, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618f292e9792, moduleTitle=Ann Oncol：局限期小细胞肺癌(LD-SCLC)患者同步放化疗+PCI后使用nivolumab+ipilimumab免疫联合强化治疗并不能改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=618f292e9792)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516685, encodeId=861f151668542, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性, objectType=article, longId=221519, objectId=836f22151965, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=836f22151965, replyNumber=0, likeNumber=32, createdTime=2021-12-05, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=836f22151965, moduleTitle=Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=836f22151965)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516684, encodeId=8271151668488, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=EP 方案同步放化疗治疗局限期小细胞肺癌的疗效分析, objectType=article, longId=220674, objectId=456f2206e4cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456f2206e4cc, replyNumber=0, likeNumber=0, createdTime=2021-11-22, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456f2206e4cc, moduleTitle=EP 方案同步放化疗治疗局限期小细胞肺癌的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=456f2206e4cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516683, encodeId=98b31516683d1, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, objectType=article, longId=220337, objectId=e64222033e7d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e64222033e7d, replyNumber=0, likeNumber=40, createdTime=2021-11-16, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e64222033e7d, moduleTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e64222033e7d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516682, encodeId=35be1516682c7, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）, objectType=article, longId=215628, objectId=4ff021562880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff021562880, replyNumber=0, likeNumber=30, createdTime=2021-08-14, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff021562880, moduleTitle=JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff021562880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516681, encodeId=8fcf151668152, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=肺癌三期不可手术的患者NSCLC体质差的，是否可以不做同步放化疗，直接化疗后免疫维持？, objectType=article, longId=214836, objectId=488c2148364c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=488c2148364c, replyNumber=0, likeNumber=34, createdTime=2021-07-28, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=488c2148364c, moduleTitle=肺癌三期不可手术的患者NSCLC体质差的，是否可以不做同步放化疗，直接化疗后免疫维持？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=488c2148364c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516680, encodeId=cb23151668075, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=Clinical Lung Cancer：老年不可切除III期非小细胞肺癌（NSCLC）患者同步放化疗后Durvalumab维持治疗的疗效：PACIFIC研究事后分析, objectType=article, longId=213772, objectId=b27f213e7214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b27f213e7214, replyNumber=0, likeNumber=44, createdTime=2021-07-07, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b27f213e7214, moduleTitle=Clinical Lung Cancer：老年不可切除III期非小细胞肺癌（NSCLC）患者同步放化疗后Durvalumab维持治疗的疗效：PACIFIC研究事后分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b27f213e7214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516679, encodeId=a7d815166e97e, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, objectType=article, longId=212429, objectId=7a5c212429e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5c212429e5, replyNumber=0, likeNumber=40, createdTime=2021-06-09, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5c212429e5, moduleTitle=JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5c212429e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516678, encodeId=242115166e8a7, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , objectType=article, longId=212089, objectId=fc5c2120893c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc5c2120893c, replyNumber=0, likeNumber=21, createdTime=2021-06-01, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc5c2120893c, moduleTitle=Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc5c2120893c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516677, encodeId=526b15166e7b5, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=JTO: Durvalumab治疗同步放化疗后Ⅲ期EGFR突变的NSCLE患者研究结果, objectType=article, longId=211907, objectId=ac0e21190e76, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0e21190e76, replyNumber=0, likeNumber=34, createdTime=2021-05-28, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0e21190e76, moduleTitle=JTO: Durvalumab治疗同步放化疗后Ⅲ期EGFR突变的NSCLE患者研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0e21190e76)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516676, encodeId=21b815166e62b, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, objectType=article, longId=205784, objectId=6b89205e84a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b89205e84a3, replyNumber=0, likeNumber=33, createdTime=2021-01-17, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b89205e84a3, moduleTitle=JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b89205e84a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516675, encodeId=da1815166e5d7, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=CLIN CANCER RES：Iniparib联合同步放化疗治疗胶质母细胞瘤, objectType=article, longId=158546, objectId=761e15854639, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=761e15854639, replyNumber=0, likeNumber=36, createdTime=2019-01-22, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=761e15854639, moduleTitle=CLIN CANCER RES：Iniparib联合同步放化疗治疗胶质母细胞瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=761e15854639)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516674, encodeId=233815166e4d6, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=ANN ONCOL：诱导化疗后序贯同步放化疗治疗鼻咽癌, objectType=article, longId=150026, objectId=359915002608, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=359915002608, replyNumber=0, likeNumber=49, createdTime=2018-10-01, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=359915002608, moduleTitle=ANN ONCOL：诱导化疗后序贯同步放化疗治疗鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=359915002608)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516673, encodeId=766815166e373, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=2018 台湾共识建议：接受同步放化疗的头颈部肿瘤患者的营养干预, objectType=article, longId=140761, objectId=e88b140e61ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e88b140e61ac, replyNumber=0, likeNumber=27, createdTime=2018-06-15, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e88b140e61ac, moduleTitle=2018 台湾共识建议：接受同步放化疗的头颈部肿瘤患者的营养干预, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e88b140e61ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516672, encodeId=742d15166e237, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=ASCO 2018：同步放化疗联合pembrolizumab巩固治疗用于不可切除III期NSCLC的II期研究, objectType=article, longId=139735, objectId=3b5d139e35b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b5d139e35b5, replyNumber=0, likeNumber=33, createdTime=2018-06-03, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b5d139e35b5, moduleTitle=ASCO 2018：同步放化疗联合pembrolizumab巩固治疗用于不可切除III期NSCLC的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b5d139e35b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516671, encodeId=b02e15166e1bb, content=<a href='/topic/show?id=a8183896891' target=_blank style='color:#2F92EE;'>#同步放化疗#</a>, objectTitle=CLIN CANCER RES：诱导化疗+同步放化疗治疗鼻咽癌, objectType=article, longId=136492, objectId=320e13649292, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=320e13649292, replyNumber=0, likeNumber=43, createdTime=2018-04-27, rootId=0, userName=12498e0fm81暂无昵称, userId=c1dd10999249, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=320e13649292, moduleTitle=CLIN CANCER RES：诱导化疗+同步放化疗治疗鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=320e13649292)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

同步放化疗

2020-05-29

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

Thorac Cancer：基于PET检查分期的食管鳞癌根治术后辅助同步放化疗(ACCRT)的疗效

2022-06-10

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

Clin Cancer Res：陈明教授团队发现不可手术的食管鳞状细胞癌（ESCC）同步放化疗中使用放疗剂量为50Gy更合适

2022-03-12

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

Front Oncol：宫颈癌根治性子宫切除术+淋巴结清扫(RHND)+辅助放疗(RT)/同步放化疗(CCRT)后复发患者的复发模式及预后因素

2022-02-06

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效

2021-12-30

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

Ann Oncol：局限期小细胞肺癌(LD-SCLC)患者同步放化疗+PCI后使用nivolumab+ipilimumab免疫联合强化治疗并不能改善患者的预后

2021-12-28

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

Front Oncol：比较同步放化疗联合诱导化疗或辅助化疗在II–IVA期鼻咽癌患者中的疗效和安全性

2021-12-05

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

EP 方案同步放化疗治疗局限期小细胞肺癌的疗效分析

2021-11-22

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响

2021-11-16

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

JAMA Oncol：二甲双胍联合同步放化疗治疗局部晚期非小细胞肺癌（NRG-LU001研究，附点评）

2021-08-14

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

肺癌三期不可手术的患者NSCLC体质差的，是否可以不做同步放化疗，直接化疗后免疫维持？

2021-07-28

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

Clinical Lung Cancer：老年不可切除III期非小细胞肺癌（NSCLC）患者同步放化疗后Durvalumab维持治疗的疗效：PACIFIC研究事后分析

2021-07-07

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

JAMA Oncol：帕博利珠单抗（Pembrolizumab）联合同步放化疗(cCRT)治疗不可切除的III期NSCLC的疗效和安全性: KEYNOTE-799。

2021-06-09

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

Lancet Oncology：Avelumab联合同步放化疗与单纯同步放化疗治疗局部晚期头颈部鳞状细胞癌：一项随机、双盲、安慰剂对照、多中心、3期试验

2021-06-01

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

JTO: Durvalumab治疗同步放化疗后Ⅲ期EGFR突变的NSCLE患者研究结果

2021-05-28

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

JAMA Oncol：3期随机试验 | 序贯放化疗 vs 同步放化疗用作早期宫颈癌术后辅助治疗的疗效

2021-01-17

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

CLIN CANCER RES：Iniparib联合同步放化疗治疗胶质母细胞瘤

2019-01-22

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

ANN ONCOL：诱导化疗后序贯同步放化疗治疗鼻咽癌

2018-10-01

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

2018 台湾共识建议：接受同步放化疗的头颈部肿瘤患者的营养干预

2018-06-15

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

ASCO 2018：同步放化疗联合pembrolizumab巩固治疗用于不可切除III期NSCLC的II期研究

2018-06-03

12498e0fm81暂无昵称 (审核中...)

前往app查看评论内容

#同步放化疗#

CLIN CANCER RES：诱导化疗+同步放化疗治疗鼻咽癌

2018-04-27

科室
- - 订阅+
  - 更多科室
工具
服务